Astellas To Set Up Branch Office In Chengdu
This article was originally published in PharmAsia News
Executive Summary
Japanese drug R&D corporation Astellas, ranked 35th on the Fortune 500 list in 2008, will establish a branch office in Chengdu to handle business in southwest and northwest China. The new office will be in charge of marketing promotion in the western region, along with bringing the world's most updated drug information, healthcare developments and market trends to hospitals and doctors. Depending on the market situation, the firm does not rule out the possibility of setting up a pharmaceutical plant or R&D center in the city. Texas Instruments is another Fortune 500 company setting up a base in Chengdu. (Click here for more - Chinese Language)
You may also be interested in...
Astellas Forecasts Earnings Decline; Says Urology Franchise Will Drive Global Growth
Astellas recently reported declining sales, operating income and profits for fiscal year 2008 due to the appreciation of the yen and the revision of Japan's drug pricing policy. The decline in sales and earnings was the first to be posted since the 2005 merger between Fujisawa and Yamanouchi Pharmaceutical
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.